The move to list Novartis’s new drug ‘Zolgensma (onasemnogene abeparvovec-xioi)’ for reimbursement benefits is now underway. The industry’s eyes are on which types of the RSA scheme will be combined for this ultra-high-priced ‘dream drug.’

Whether Zolgensma will be listed for insurance benefits is the focus of attention in the industry. The industry-wide interest was approved in May in Korea as a single shot of Zolgensma costs over 2 billion won. Of course, when compared to other existing drugs that require spending 300 to 500 million won every year for the rest of one's life, this ‘one-shot’ treatment cannot strictly be called an ‘ultra extensive' drug. Nevertheless, it is true that the gover